Role of Lateral Hypothalamic Orexin (Hypocretin) Neurons in Alcohol Use and Abuse: Recent Advances

被引：0
作者：
Walker L.C. [1 ,2 ]
Ch’ng S.S. [1 ,2 ]
Lawrence A.J. [1 ,2 ]
机构：
[1] The Florey Institute of Neuroscience and Mental Health, Parkville, 3052, VIC
[2] Florey Department of Neuroscience and Mental Health, The University of Melbourne, Parkville, 3010, VIC
来源：
Current Pharmacology Reports | 2016年 / 2卷 / 6期
基金：
英国医学研究理事会;
关键词：
Addiction; Alcohol; Hypocretin; Lateral hypothalamus; Orexin;
D O I：
10.1007/s40495-016-0069-7
中图分类号：
学科分类号：
摘要：
Purpose of Review: Alcohol use disorders (AUDs) are chronic relapsing disorders with the modest efficacy of current medications. The US Food and Drug Administration (FDA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) approval of the dual orexin (OX) receptor antagonist, suvorexant for the treatment of insomnia, may enable repurposing of this drug for the treatment of other diseases. Here, we summarize and reflect on the most recent research on the role of OX neurons in alcohol use and abuse. Recent Findings: OX neurons regulate alcohol intake and seeking, although their involvement in different aspects of alcohol consumption/seeking, specific loci of action and interactions with other transmitter systems are still being clarified. Summary: Recent studies have identified anatomic loci of action and interactions between OX and other neuropeptides that drive alcohol seeking. Future studies are required to fully elucidate these behaviors, in which optogenetic and chemogenetic approaches may prove useful. © 2016, Springer International Publishing AG.
引用
收藏
页码：241 / 252
页数：11
相关论文
共 94 条
  • [1] Causes of death, Data sources and methods, (2008)
  • [2] Rehm J., Mathers C., Popova S., Thavorncharoensap M., Teerawattananon Y., Patra J., Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders, Lancet, 373, 9682, pp. 2223-2233, (2009)
  • [3] Anton R.F., Pharmacologic approaches to the management of alcoholism, J Clin Psychiatry, 62, pp. 11-17, (2001)
  • [4] Cowen M.S., Chen F., Lawrence A.J., Neuropeptides: implications for alcoholism, J Neurochem, 89, 2, pp. 273-285, (2004)
  • [5] Jupp B., Lawrence A.J., New horizons for therapeutics in drug and alcohol abuse, Pharmacol Ther, 125, 1, pp. 138-168, (2010)
  • [6] Litten R.Z., Wilford B.B., Falk D.E., Ryan M.L., Fertig J.B., Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety, Subst Abus, 37, 2, pp. 286-298, (2016)
  • [7] Khoo S.Y., Brown R.M., Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?, CNS Drugs, 28, 8, pp. 713-730, (2014)
  • [8] De Lecea L., Kilduff T., Peyron C., Gao X.-B., Foye P., Danielson P., Et al., The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc Natl Acad Sci U S A, 95, 1, pp. 322-327, (1998)
  • [9] Sakurai T., Amemiya A., Ishii M., Matsuzaki I., Chemelli R.M., Tanaka H., Et al., Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior, Cell, 92, 4, pp. 573-585, (1998)
  • [10] Ammoun S., Holmqvist T., Shariatmadari R., Oonk H.B., Detheux M., Parmentier M., Et al., Distinct recognition of OX1 and OX2Receptors by orexin peptides, J Pharm Expl Ther, 305, 2, pp. 507-514, (2003)
12345678910